• Two new 4-year distribution agreements in China with long-term partners
• $20m agreement with sleep diagnostics distributor in Northern China
• $4.4m agreement with sleep and neurological distributor in Eastern China
• Both agreements include a minimum +10% per annum growth commitment

Compumedics Limited, a leading global medical device company specialising in sleep, brain, and ultrasonic blood flow monitoring, has announced the signing of two new 4-year distribution agreements with long-standing partners in China. The agreements, valued at a total of A$24.4 million, will further strengthen Compumedics' presence across key regions in Asia. The first agreement, worth A$20 million, extends the company's established partnership with its long-term Northern China distributor focused on sleep diagnostics. The second agreement, valued at A$4.4 million, renews a long-standing relationship with an Eastern China distributor focused on sleep and neurology. Both agreements include a minimum +10% per annum growth commitment, providing a clear trajectory for expanding sales in one of Compumedics' most strategically important markets, where the company has had a significant involvement for over 20 years. This growth reflects the company's continued strategic shift toward a more diversified and resilient revenue base, both geographically and across product lines. The strengthening of key relationships in Asia, particularly in China, reinforces Compumedics' ability to drive consistent growth through its core sleep and neurology platforms. With a solid foundation in place and demand accelerating across multiple international markets, Compumedics remains well positioned to scale efficiently and deliver sustained, profitable growth into FY26 and beyond.

The two new 4-year distribution agreements in China include a minimum +10% per annum growth commitment, providing a clear trajectory for expanding sales in one of Compumedics' most strategically important markets.

Compumedics remains well positioned to scale efficiently and deliver sustained, profitable growth into FY26 and beyond, with a solid foundation in place and demand accelerating across multiple international markets.